Heptapeptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-05-23. Where a claim depends on a specific study, the study is described rather than over-claimed.
Published work on this peptide almost always uses intranasal delivery, with drops or a spray applied to the nasal mucosa. Some animal experiments have used subcutaneous or intraperitoneal injection, and a smaller number have compared routes directly. Oral administration is not a focus of the literature, because short peptides of this size are broken down by digestive enzymes and cross intestinal barriers poorly. How much of an intranasal dose reaches the bloodstream intact in humans remains an open question.
Animal studies have examined behaviour in tests of anxiety, memory retention and stress response, and several report changes in neurotrophic or neurotransmitter-related markers. The human evidence base is much smaller, consisting mainly of short trials conducted in Russia with limited reporting in English-language journals. Sample sizes are modest and outcome measures vary between studies, so the findings are best described as preliminary. Independent replication under modern trial standards has not been widely reported.
Outside its country of origin the compound is generally handled as a research chemical rather than an approved medicine. No regulatory approval from the United States Food and Drug Administration or the European Medicines Agency has been granted for human use. Identity and purity are normally checked by reverse-phase high-performance liquid chromatography, with mass spectrometry used to confirm the molecular mass. Lyophilised material is stored cold and desiccated, and repeated freeze-thaw cycles are avoided.
Purity assessment relies mainly on reverse-phase high-performance liquid chromatography with ultraviolet detection. Because the peptide lacks a strong chromophore, detection often uses backbone absorbance near 214 nm. Identity is confirmed by mass spectrometry, typically electrospray ionization or matrix-assisted laser desorption, comparing the measured mass against the expected value. Amino acid analysis can verify composition after acid hydrolysis. Diastereomer content and residual counterions are reported less often, although both can influence biological assays.
Lyophilized material is generally stable for extended periods when kept dry at or below minus twenty degrees Celsius. Working solutions are less stable, and common practice is to aliquot and freeze them so that repeated freeze-thaw cycles are avoided. Aqueous solutions are sensitive to pH extremes and to microbial growth, so short-term storage at refrigerator temperature is typical. Oxidation and hydrolysis are the principal degradation routes. Reconstitution with sterile water or a mild buffer is standard, and solutions should be protected from light.
Regulatory treatment varies by jurisdiction. In Russia the compound is a registered prescription product, while in the European Union and the United States it is generally handled as a research chemical without a marketing authorization. Suppliers therefore operate outside pharmaceutical oversight, and buyers rely on supplier documentation for purity and identity claims. Chain of custody and third-party testing are the main verification tools. Analysts note that the absence of a pharmacopoeial monograph for research-grade material limits standardization across vendors.
| Property | Value | Notes |
|---|---|---|
| Common route | Intranasal | Also injected in some animal work |
| Solubility class | Freely soluble in water | Solid form is hygroscopic |
| Typical storage | About -20 degrees Celsius | Keep desiccated and dark |
| Purity method | Reverse-phase HPLC | Reported as area percent |
| Confirmatory method | Mass spectrometry | Verifies expected molecular mass |
Lyophilized selank is normally supplied as a dry powder and is considered stable for extended periods when kept cold and dry. Moisture uptake is the main practical threat, because absorbed water promotes both hydrolysis and aggregation in the solid state. Vials are usually warmed to room temperature before opening so that condensation does not form on the powder. Supplier documentation commonly specifies -20 °C for routine storage, with -80 °C used for material intended to be archived for years.
Once dissolved, the peptide is markedly less stable than the dry powder. Aqueous solutions are subject to backbone hydrolysis and to microbial growth when they are handled without sterile technique. Buffered solutions near neutral pH are common for short-term laboratory work, while acidic conditions are sometimes used to improve solubility. Analytical laboratories generally prepare working solutions fresh rather than storing them, and a residual water film left in a reopened vial can seed degradation even when the container appears dry.
Proposed mechanisms centre on modulation of the GABAergic system, with reports of altered expression of genes related to GABA-A receptor subunits and changed monoamine turnover. Some studies describe inhibition of enkephalinase, the enzyme that degrades endogenous enkephalins, which may prolong opioid peptide signalling. Effects on brain-derived neurotrophic factor and on cytokine expression have also been reported. These findings come largely from animal models and small human studies, and the precise primary target remains unresolved.
Published clinical evidence is limited. Most controlled trials were conducted in Russia, enrolled modest numbers of participants, and appeared in Russian-language journals, which restricts independent verification. Reported outcomes include lower anxiety scores, improved attention and memory measures, and changes in fatigue ratings. Reviews written in English note methodological limitations such as small samples and inconsistent endpoints. Whether the compound produces clinically meaningful benefit relative to established anxiolytics is therefore an open question rather than an established finding.
The majority of tulip cultivars are classified in the taxon Tulipa gesneriana. They have usually several species in their direct background, but most have been derived from Tulipa suaveolens. Tulipa gesneriana is in itself an early hybrid of complex origin and is probably not the same taxon as was described by Conrad Gessner in the 16th century. The UK's National Collection of English florists' tulips and Dutch historic tulips, dating from the early 17th century to c. 1960, is held by Polly Nicholson at Blackland House, near Calne in Wiltshire.
=== Media === The Spectator opined that "In any discipline, we seek only to discover who is the fastest, or the strongest, the most accurate or the most coordinated. What's absolutely crucial, at least as far as retaining spectator interest goes, is that the advantage is natural." The Daily Telegraph's sports writer commented that "Remarkably it seems a more fleshed-out idea than the European Super League". Cyclist wondered who would be willing to sponsor the event, noting that as of late July 2023, no sponsors were mentioned on TEG's website. Writing for The Globe and Mail, Alex Cyr said, "I will admit, I am incredibly curious to see an 'enhanced' person running faster than Usain Bolt, or swimming better than Michael Phelps. But I would not want to be that person, and I bet that neither will the serious athletes who have so far managed to avoid doping infractions." The Independent said that while the sporting world has been mostly dismissive, "D'Souza is intelligent and well-connected, and he has brought down big targets before. So when he says it's going to happen, he is deadly serious." The Sydney Morning Herald's sport columnist said that "the Enhanced Games are a dangerous, iniquitous concept." Outsports criticized D'Souza's use of LGBTQ language like "coming out" to describe athletes openly using performance-enhancing drugs. D'Souza is an out gay man. OutKick's writer said in February 2025 "Humans LOVE modern gladiators accomplishing feats that none of us ever could. The Olympics can still have non-tainted records ...
=== Hemoglobin delivery === Aquasomes have been explored as carriers for hemoglobin throughout the body. In a 2002 study by Khopade, Khopade, and Jain, aquasomes were used to act as red blood cell substitutes with hemoglobin attached to the oligomer surface. Aquasomes in this application demonstrated minimal toxicity while obtaining a hemoglobin content of 80%, supplying blood and oxygen in a manner similar to regular red blood cells. Hemoglobin aquasomes with spherical hydroxyapatite cores have been shown to retain oxygen-affinity and cooperativity for 30 days in rats in vivo, causing no red blood cell hemolysis or blood coagulation, demonstrating potential capability as effective oxygen transporters. Additionally, aquasomes protected hemoglobin from degradation while maintaining hemoglobin function. Future exploration of aquasomes as hemoglobin carriers may explore controlled release of the aquasomes themselves to mimic typical oxygen release properties to aid in biomedical applications that require specific targeting and delivery of hemoglobin.
Sources: en.wikipedia.org
8136Kr + e− → 8135Br + νe All emitted neutrinos are of the same energy. In proton-rich nuclei where the energy difference between the initial and final states is less than 2mec2, β+ decay is not energetically possible, and electron capture is the sole decay mode. If the captured electron comes from the innermost electron shell of the atom, called the K-shell, it is called K-capture. If it comes from the second or L-shell, the process is called L-capture, and so on, with higher level labels increasing with the alphabet. Electron capture is a competing (simultaneous) decay process for all nuclei that can undergo β+ decay. The converse, however, is not true: electron capture is the only type of decay that is allowed in proton-rich nuclides that do not have sufficient energy to emit a positron and neutrino.
Various theories exist as to whether people who sustain carotid and vertebral artery dissection, even if they do not have a connective tissue disorder, have an underlying vulnerability. Biopsy samples of skin and other arteries has indicated that this might be a possibility, but no genetic defect in collagen or elastin genes has been convincingly proven. Other studies have indicated inflammation of the blood vessels, as measured by highly sensitive C-reactive protein (hsCRP, a marker of inflammation) in the blood. Once dissection has occurred, two mechanisms contribute to the development of stroke symptoms. Firstly, the flow through the blood vessel may be disrupted due to the accumulation of blood under the vessel wall, leading to ischemia (insufficient blood supply). Secondly, irregularities in the vessel wall and turbulence increase the risk of thrombosis (the formation of blood clots) and embolism (migration) of these clots of the brain. From various lines of evidence, it appears that thrombosis and embolism is the predominant problem. Subarachnoid hemorrhage due to arterial rupture typically occurs if the dissection extends into the V4 section of the artery. This may be explained by the fact that the arterial wall is thinner and lacks a number of structural supports in this section.
== Other uses == C. P. (name), shared by several notable individuals Camp (disambiguation); the US Census Bureau uses "Cp" as a shorthand for "Camp" Ceteris paribus (cp), a Latin phrase commonly rendered as "all other things being equal" Colored people See also colored people's time Member of the Passionists, a Roman Catholic religious order (post-nominal letters C.P.) Compare, a directive to the reader to compare to a cited source (used interchangeably with "cf."); see List of Latin abbreviations
Sources: en.wikipedia.org
Most published work uses intranasal application, either as drops or as a nasal spray. Injection routes appear in a smaller set of animal experiments. Oral use is uncommon in the literature because peptide breakdown and poor absorption limit this route.
Reported human trials are few, brief and originate mainly from one country. They describe effects on anxiety-related measures, but sample sizes are small and reporting is limited. The results are widely regarded as preliminary rather than confirmed.
Reverse-phase liquid chromatography is used to assess purity and separation of related impurities. Mass spectrometry confirms that the observed molecular mass matches the expected peptide. A certificate of analysis from the supplier is the usual document of record.
Purity is usually reported as an HPLC area percentage, most often measured at 214 nm. Identity is confirmed separately by mass spectrometry. A certificate of analysis should state both the method and the observed value.